The Community-Acquired Bacterial Pneumonia drugs in development market research report provides comprehensive information on the therapeutics under development for Community-Acquired Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Community-Acquired Bacterial Pneumonia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Community-Acquired Bacterial Pneumonia and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Community-Acquired Bacterial Pneumonia by ten companies/universities/institutes. The top development phase for Community-Acquired Bacterial Pneumonia is phase i with three drugs in that stage. The Community-Acquired Bacterial Pneumonia pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Community-Acquired Bacterial Pneumonia pipeline products market are: Wockhardt, FUJIFILM Toyama Chemical and KBP Biosciences.
The key targets in the Community-Acquired Bacterial Pneumonia pipeline products market include DNA Gyrase, DNA Topoisomerase IV, and 23S Ribosomal RNA.
The key mechanisms of action in the Community-Acquired Bacterial Pneumonia pipeline product include DNA Gyrase Inhibitor with three drugs in Phase II. The Community-Acquired Bacterial Pneumonia pipeline products include six routes of administration with the top ROA being Intravenous and two key molecule types in the Community-Acquired Bacterial Pneumonia pipeline products market including Small Molecule, and Monoclonal Antibody.
Community-Acquired Bacterial Pneumonia overview
Community-acquired pneumonia is defined as pneumonia that is acquired outside the hospital. The most commonly identified pathogens are Streptococcus pneumoniae, Haemophilus influenzae, atypical bacteria (ie, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella species), and viruses. Symptoms and signs are fever, cough, sputum production, pleuritic chest pain, dyspnea, tachypnea, and tachycardia
For a complete picture of Community-Acquired Bacterial Pneumonia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
